# Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

> **NCT01175200** · NA · COMPLETED · sponsor: **Ascopharm Groupe Novasco** · enrollment: 82 (actual)

## Conditions studied

- Anti Platelet Effects

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Prasugrel
- **DRUG:** Lansoprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01175200
- **Lead sponsor:** Ascopharm Groupe Novasco
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2012-07-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01175200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01175200, "Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01175200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*